F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comHester Biosciences Ltd is one of India’s leading animal healthcare companies, engaged in the production and distribution of vaccines and healthcare products for poultry and livestock. With its strong presence in both domestic and international markets, the company has carved out a niche in animal health innovation. In this article, we’ll explore Hester Biosciences’ share price target from 2025 to 2030, along with key business insights.
Let’s analyze the company’s fundamentals, stock performance, and long-term outlook.
| Detail | Value |
|---|---|
| Current Price | ₹1,936.30 |
| Previous Close | ₹1,893.70 |
| Day's High | ₹1,936.30 |
| Day's Low | ₹1,878.20 |
| 52-Week High | ₹2,786.10 |
| 52-Week Low | ₹1,242.95 |
| Market Capitalization | ₹1,610 Cr |
| Beta (Volatility) | 0.75 |
| Book Value per Share | ₹314.33 |
| Face Value | ₹10 |
| Dividend Yield | 0.37% |
Founded in 1987, Hester Biosciences has emerged as one of the largest poultry and animal vaccine manufacturers in India. The company’s product portfolio covers vaccines for poultry diseases, large animals, and health supplements. Hester has also been expanding its global footprint with exports to Africa, the Middle East, and Asia.
India’s second-largest animal vaccine manufacturer.
Strong focus on R&D and product innovation.
Expanding international presence with WHO-prequalified facilities.
Consistent revenue from veterinary products.
Benefiting from growing demand for animal healthcare and food safety.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 53.73% |
| Retail & Others | 45.73% |
| Foreign Institutions | 0.52% |
| Other Domestic Institutions | 0.02% |
This shows promoter confidence and strong retail participation, making it an attractive mid-cap stock on NSE and BSE.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 1,950 | 2,050 |
| 2026 | 2,150 | 2,300 |
| 2027 | 2,400 | 2,600 |
| 2028 | 2,650 | 2,850 |
| 2029 | 2,900 | 3,150 |
| 2030 | 3,200 | 3,500 |
These projections are based on the company’s growth strategy, financial performance, demand outlook in animal healthcare, and global expansion.
In 2025, Hester is expected to maintain stable growth supported by demand for poultry and livestock vaccines.
Why?
Rising consumption of poultry and dairy products in India.
Improved production efficiency and R&D pipeline.
Stable volatility (Beta: 0.75).
Investment Advice: Good for staggered buying during dips; long-term investors can start accumulation.
By 2026, expansion in exports and new product launches may fuel growth.
Why?
WHO-prequalified vaccines boosting international orders.
Increased demand for animal health supplements.
Better margins from high-value products.
Investment Advice: Hold for medium term; monitor quarterly results for consistency.
In 2027, the company could achieve stronger revenue from its African subsidiaries and partnerships.
Why?
Global market expansion.
Demand in emerging markets for livestock vaccines.
Consistent promoter holding ensures stability.
Investment Advice: Continue SIPs or reinvest dividends for long-term compounding.
By 2028, Hester could cross the ₹2,800 mark.
Why?
Higher operational efficiency.
R&D-driven product portfolio expansion.
Government focus on livestock health programs.
Investment Advice: Attractive mid-cap growth stock; hold for CAGR gains.
Steady growth in global animal health market may push valuations further.
Why?
Rising exports.
Strategic collaborations with global players.
Strong balance sheet and cash flows.
Investment Advice: Suitable for medium- to long-term investors seeking sectoral diversification.
By 2030, Hester may emerge as a key international animal healthcare brand.
Why?
Sustained market demand.
Continued innovation in vaccines.
Robust promoter-driven management.
Investment Advice: Excellent long-term wealth creation potential.
Yes, Hester Biosciences is an emerging player in the animal healthcare sector with strong fundamentals, stable promoter holding, and a growing global presence.
Leadership in poultry and animal vaccines.
Expanding exports and global partnerships.
Strong R&D and product innovation pipeline.
Consistent promoter trust.
Dependency on livestock market trends.
Regulatory challenges in vaccine exports.
Competition from multinational players.
Hester Biosciences Ltd is a promising mid-cap stock listed on NSE and BSE. With a current market capitalization of ₹1,610 Cr and strong fundamentals, the company is well-positioned for long-term growth. Analysts believe Hester’s share could touch ₹3,500 by 2030 if current strategies play out successfully.
For investors looking for exposure in the growing animal healthcare sector, Hester Biosciences offers a balanced opportunity of stability and growth.
What is the share price target for Hester Biosciences in 2025?
The target is between ₹1,950 – ₹2,050.
What is the 2030 target price of Hester Biosciences?
Analysts project between ₹3,200 – ₹3,500.
Is Hester Biosciences a good long-term stock?
Yes, due to its strong fundamentals, R&D pipeline, and global expansion.
What is the current market cap of Hester Biosciences?
As of August 2025, the market cap is around ₹1,610 Cr.
Does Hester Biosciences pay dividends?
Yes, with a dividend yield of 0.37%.
Who are the promoters of Hester Biosciences?
Promoters hold 53.73% of the shares.
What is the 52-week high and low of Hester Biosciences?
High: ₹2,786.10, Low: ₹1,242.95.
Is Hester Biosciences a volatile stock?
No, with a Beta of 0.75, it has lower volatility compared to market averages.
What sector does Hester Biosciences belong to?
Animal healthcare and veterinary pharmaceuticals.
Should I buy Hester Biosciences stock now?
It depends on your investment goals; consult a financial advisor before investing.
???? Disclaimer: This article is for educational purposes only. Please consult a certified financial advisor before making investment decisions.
Register & Login